Full Text Journal Articles by
Author Sandro Pignata

Advertisement

Find full text journal articles






Acute Toxicity in Hypofractionated/Stereotactic Prostate Radiotherapy of Elderly Patients: Use of the Image-guided Radio Therapy (IGRT) Clarity System.

Rossella DI Franco, Valentina Borzillo, Domingo Alberti, Gianluca Ametrano, Angela Petito, Andrea Coppolaro, Ilaria Tarantino, Sabrina Rossetti, Sandro Pignata, Gelsomina Iovane, Sisto Perdonà, Giuseppe Quarto, Giovanni Grimaldi, Alessandro Izzo, Luigi Castaldo, Raffaele Muscariello, Marcello Serra, Gaetano Facchini, Paolo Muto,

<h4>Background</h4>The use of intra-fractional monitoring and correction of prostate position with the Image Guided Radio Therapy (IGRT) system can increase the spatial accuracy of dose delivery. Clarity is a system used for intrafraction prostate-motion management, it provides a real-time visualization of prostate with a transperineal ultrasound. The aim of this ... Read more >>

In Vivo (In vivo (Athens, Greece))
[2021, 35(3):1849-1856]

Cited: 0 times

View full text PDF listing >>



Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33).

Lucia Musacchio, Vanda Salutari, Sandro Pignata, Elena Braicu, David Cibula, Nicoletta Colombo, Jean Sebastien Frenel, Flora Zagouri, Vittoria Carbone, Viola Ghizzoni, Serena Giolitto, Elena Giudice, Maria Teresa Perri, Caterina Ricci, Giovanni Scambia, Domenica Lorusso,

<h4>Background</h4>Platinum-resistant ovarian cancer patients have a poor prognosis and few treatment options are available. Preclinical and clinical data demonstrated that the combination of poly-ADP ribose polymerase inhibitors with immune checkpoint inhibitors could have a synergistic antitumor activity in this setting of patients.<h4>Primary objective</h4>The primary objective is to assess the efficacy ... Read more >>

Int J Gynecol Cancer (International journal of gynecological cancer : official journal of the International Gynecological Cancer Society)
[2021, 31(10):1369-1373]

Cited: 0 times

View full text PDF listing >>



Advertisement

Impact of COVID-19 on medical treatment patterns in gynecologic oncology: a MITO group survey.

Raffaella Cioffi, Giulia Sabetta, Emanuela Rabaiotti, Alice Bergamini, Luca Bocciolone, Giorgio Candotti, Massimo Candiani, Giorgio Valabrega, Giorgia Mangili, Sandro Pignata, ,

<h4>Objective</h4>COVID-19 is a global public health emergency. The increasing spread of COVID-19 presents challenges for the clinical care of patients with gynecological tumors. The Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITO) performed a survey to evaluate the impact of the COVID-19 pandemic on medical treatment of gynecological ... Read more >>

Int J Gynecol Cancer (International journal of gynecological cancer : official journal of the International Gynecological Cancer Society)
[2021, 31(10):1363-1368]

Cited: 0 times

View full text PDF listing >>



The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas.

Benoit You, Gilles Freyer, Antonio Gonzalez-Martin, Stephanie Lheureux, Iain McNeish, Richard T Penson, Sandro Pignata, Eric Pujade-Lauraine,

In patients with advanced ovarian carcinomas, the first-line treatment has historically relied on debulking surgery and platinum-based chemotherapy. If the major therapeutic/prognostic role of the surgery part is well understood, and integrated in disease-management algorithms, the impact of chemotherapy efficacy has been insufficiently addressed. This review describes the main indicators ... Read more >>

Cancer Treat Rev (Cancer treatment reviews)
[2021, 100:102294]

Cited: 0 times

View full text PDF listing >>



Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial.

Raimondo Di Liello, Laura Arenare, Francesco Raspagliesi, Giovanni Scambia, Carmela Pisano, Nicoletta Colombo, Simona Frezzini, Germana Tognon, Grazia Artioli, Angiolo Gadducci, Rossella Lauria, Annamaria Ferrero, Saverio Cinieri, Andrea De Censi, Enrico Breda, Paolo Scollo, Ugo De Giorgi, Andrea Alberto Lissoni, Dionyssios Katsaros, Domenica Lorusso, Vanda Salutari, Sabrina Chiara Cecere, Mariateresa Lapresa, Margherita Nardin, Giorgio Bogani, Mariagrazia Distefano, Stefano Greggi, Piera Gargiulo, Clorinda Schettino, Ciro Gallo, Gennaro Daniele, Daniela Califano, Francesco Perrone, Sandro Pignata, Maria Carmela Piccirillo,

<h4>Introduction</h4>The use of routine antithrombotic prophylaxis is not recommended for advanced cancer patients receiving chemotherapy. The effect of bevacizumab-containing therapy on the risk of thromboembolic events remains controversial in ovarian cancer patients. We report on the incidence of thromboembolic events and the prevalence of antithrombotic therapy in patients enrolled in ... Read more >>

Int J Gynecol Cancer (International journal of gynecological cancer : official journal of the International Gynecological Cancer Society)
[2021, 31(10):1348-1355]

Cited: 0 times

View full text PDF listing >>



Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

Toni K Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Thomas Ferguson, Yen-Hwa Chang, Jaroslav Hajek, Stefan N Symeonides, Jae Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross-Goupil, Mauricio Mahave, Naomi B Haas, Piotr Sawrycki, Howard Gurney, Christine Chevreau, Bohuslav Melichar, Evgeniy Kopyltsov, Ajjai Alva, John M Burke, Gurjyot Doshi, Delphine Topart, Stephane Oudard, Hans Hammers, Hiroshi Kitamura, Jens Bedke, Rodolfo F Perini, Pingye Zhang, Kentaro Imai, Jaqueline Willemann-Rogerio, David I Quinn, Thomas Powles, ,

<h4>Background</h4>Patients with renal-cell carcinoma who undergo nephrectomy have no options for adjuvant therapy to reduce the risk of recurrence that have high levels of supporting evidence.<h4>Methods</h4>In a double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, patients with clear-cell renal-cell carcinoma who were at high risk for recurrence ... Read more >>

N Engl J Med (The New England journal of medicine)
[2021, 385(8):683-694]

Cited: 0 times

View full text PDF listing >>



Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators.

Marco Stellato, Giuseppe Procopio, Ugo De Giorgi, Marco Maruzzo, Davide Bimbatti, Alessia Mennitto, Andrea Sbrana, Giandomenico Roviello, Chiara Casadei, Pierangela Sepe, Sandro Pignata, Daniele Santini,

<h4>Background</h4>Severe immune-related Adverse Events (irAEs) develop in 10-27% of patients treated with Immune-Oncology (IO) [Powles (Lancet 391:748-757, 2018); Galsky (Lancet 395:1547-1557, 2020); Haanen (Ann Oncol 28:119-142, 2017)]. The aim of our study was to evaluate efficacy and clinical outcome of metastatic renal cell carcinoma (mRCC) patients who stopped Immune Checkpoint ... Read more >>

J Transl Med (Journal of translational medicine)
[2021, 19(1):328]

Cited: 0 times

View full text PDF listing >>



Oligometastatic prostate cancer treatment.

Sabrina Rossetti, Marilena Di Napoli, Carmela Pisano, Sabrina C Cecere, Rosa Tambaro, Jole Ventriglia, Anna Passarelli, Gelsomina Iovane, Florinda Feroce, Secondo Lastoria, Francesca Di Gennaro, Paolo Muto, Valentina Borzillo, Rossella Di Franco, Sisto Perdonà, Giuseppe Quarto, Sandro Pignata,

Oligometastatic prostate cancer is an intermediate state between localized disease and widespread metastasis. Its biological and clinical peculiarities are still to be elucidated. New imaging techniques contribute to the detection of patients with oligometastatic disease. PET/CT scanning with prostate-specific membrane antigen can improve the selection of men with true early, low-volume ... Read more >>

Future Oncol (Future oncology (London, England))
[2021, 17(29):3893-3899]

Cited: 0 times

View full text PDF listing >>



Real-world experience with trabectedin for the treatment of recurrent ovarian cancer.

Ignacio Romero, José Antonio López-Guerrero, Sandro Pignata,

<b>Introduction</b>: The efficacy and safety of trabectedin/pegylated liposomal doxorubicin (trabectedin/PLD) in patients with recurrent ovarian cancer have been demonstrated in randomized clinical studies. Real-world evidence is a subsequent necessary step for completing information from clinical practice. In the case of trabectedin/PLD, this evidence derives from prospective studies, retrospective analyses, and ... Read more >>

Expert Rev Anticancer Ther (Expert review of anticancer therapy)
[2021, 21(10):1089-1095]

Cited: 0 times

View full text PDF listing >>



Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study).

Melissa Bersanelli, Sebastiano Buti, Alessio Cortellini, Marco Bandini, Giuseppe Luigi Banna, Filippo Pederzoli, Elena Farè, Daniele Raggi, Patrizia Giannatempo, Ugo De Giorgi, Umberto Basso, Tania Losanno, Daniele Santini, Claudia Mucciarini, Marcello Tucci, Rosa Tambaro, Azzurra Farnesi, Orazio Caffo, Antonello Veccia, Emanuele Naglieri, Alberto Briganti, Giuseppe Procopio, Sandro Pignata, Andrea Necchi,

<h4>Background</h4>Immune checkpoint inhibitors (ICIs) are currently the standard of care for metastatic urothelial cancer (mUC) after the failure of previous platinum-based chemotherapy. The choice of further therapy after ICI progression is a new challenge, and scarce data support it. We aimed to examine the outcomes of mUC patients after progression ... Read more >>

Clin Med Insights Oncol (Clinical Medicine Insights. Oncology)
[2021, 15:11795549211021667]

Cited: 0 times

View full text PDF listing >>



Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study).

Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, Marco Maruzzo, Ugo De Giorgi, Paolo Pedrazzoli, Andrea Sbrana, Paolo Andrea Zucali, Cristina Masini, Emanuele Naglieri, Giuseppe Procopio, Sara Merler, Laura Tomasello, Lucia Fratino, Cinzia Baldessari, Riccardo Ricotta, Stefano Panni, Veronica Mollica, Maria Sorarù, Matteo Santoni, Alessio Cortellini, Veronica Prati, Hector Josè Soto Parra, Marco Stellato, Francesco Atzori, Sandro Pignata, Carlo Messina, Marco Messina, Franco Morelli, Giuseppe Prati, Franco Nolè, Francesca Vignani, Alessia Cavo, Giandomenico Roviello, Francesco Pierantoni, Chiara Casadei, Melissa Bersanelli, Silvia Chiellino, Federico Paolieri, Matteo Perrino, Matteo Brunelli, Roberto Iacovelli, Camillo Porta, Sebastiano Buti, Giuseppe Fornarini,

<h4>Background</h4>Despite the survival advantage, not all metastatic renal cell carcinoma (mRCC) patients achieve a long-term benefit from immunotherapy. Moreover, the identification of prognostic biomarkers is still an unmet clinical need.<h4>Methods</h4>This multicenter retrospective study investigated the prognostic role of peripheral-blood inflammatory indices and clinical factors to develop a novel prognostic score ... Read more >>

Ther Adv Med Oncol (Therapeutic advances in medical oncology)
[2021, 13:17588359211019642]

Cited: 0 times

View full text PDF listing >>



Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study.

Sabrina Chiara Cecere, Lucia Musacchio, Michele Bartoletti, Vanda Salutari, Laura Arenare, Domenica Lorusso, Graziana Ronzino, Rossella Lauria, Gennaro Cormio, Emanuele Naglieri, Paolo Scollo, Claudia Marchetti, Francesco Raspagliesi, Stefano Greggi, Saverio Cinieri, Alice Bergamini, Michele Orditura, Giorgio Valabrega, Giovanni Scambia, Fabio Martinelli, Elisabetta De Matteis, Cinzia Cardalesi, Vera Loizzi, Giorgia Perniola, Claudia Carella, Giuseppa Scandurra, Gaia Giannone, Sandro Pignata,

<h4>Introduction</h4>The role of cytoreductive surgery in the poly-ADP ribose polymerase inhibitors era is not fully investigated. We evaluated the impact of surgery performed prior to platinum-based chemotherapy followed by olaparib maintenance in platinum-sensitive BRCA-mutated recurrent ovarian cancer.<h4>Methods</h4>This retrospective study included platinum-sensitive recurrent ovarian cancer BRCA-mutated patients from 13 Multicenter Italian ... Read more >>

Int J Gynecol Cancer (International journal of gynecological cancer : official journal of the International Gynecological Cancer Society)
[2021, 31(7):1031-1036]

Cited: 0 times

View full text PDF listing >>



INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2).

Melissa Bersanelli, Diana Giannarelli, Ugo De Giorgi, Sandro Pignata, Massimo Di Maio, Alberto Clemente, Elena Verzoni, Raffaele Giusti, Marilena Di Napoli, Giuseppe Aprile, Paola Ermacora, Annamaria Catino, Vieri Scotti, Francesca Mazzoni, Pamela Francesca Guglielmini, Antonello Veccia, Marco Maruzzo, Ernesto Rossi, Francesco Grossi, Chiara Casadei, Corrado Ficorella, Vincenzo Montesarchio, Francesco Verderame, Mimma Rizzo, Giorgia Guaitoli, Lucia Fratino, Caterina Accettura, Manlio Mencoboni, Fable Zustovich, Cinzia Baldessari, Saverio Cinieri, Andrea Camerini, Letizia Laera, Mariella Sorarù, Paolo Andrea Zucali, Valentina Guadalupi, Francesco Leonardi, Marcello Tiseo, Michele Tognetto, Francesco Di Costanzo, Carmine Pinto, Giorgia Negrini, Antonio Russo, Maria R Migliorino, Marco Filetti, Sebastiano Buti, ,

<h4>Background</h4>Until now, no robust data supported the efficacy, safety and recommendation for influenza vaccination in patients with cancer receiving immune checkpoint inhibitors (ICIs).<h4>Methods</h4>The prospective multicenter observational INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors (INVIDIa-2) study investigated the clinical effectiveness of influenza vaccination in patients with advanced cancer receiving ... Read more >>

J Immunother Cancer (Journal for immunotherapy of cancer)
[2021, 9(5):]

Cited: 0 times

View full text PDF listing >>



Response to letter entitled: Re: Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? An international multicenter analysis.

Alice Bergamini, Naveed Sarwar, Gabriella Ferrandina, Giovanna Scarfone, Dee Short, Xianne Aguiar, Cristina Camnasio, Baljeet Kaur, Philip M Savage, Gennaro Cormio, Adrian Lim, Sandro Pignata, Giorgia Mangili, Michael J Seckl,

Eur J Cancer (European journal of cancer (Oxford, England : 1990))
[2021, 152:257-258]

Cited: 0 times

View full text PDF listing >>



Efficacy of Immunotherapy in Advanced Renal Cell Carcinoma (RCC) Patients Despite the Early Treatment Interruption Due to Serious Immune-related Adverse Events. Meet-Uro 13 Trial on Behalf of the MeetUro Investigators

Marco Stellato, Giuseppe Procopio, Ugo De Giorgi, Marco Maruzzo, Davide Bimbatti, Alessia Mennitto, Andrea Sbrana, Giandomenico Roviello, Chiara Casadei, Pierangela Sepe, Sandro Pignata, Daniele Santini,

<h4>Background: </h4> Severe immune-related Adverse Events (irAEs) develop in 10-27% of patients treated with anti-Cytotoxic T-Lymphocyte Antigen (CTLA)-4, in amount 12-20% of patients treated with anti-programmed cell death (PD)-1 and 15-20% of patients treated with anti-programmed death-ligand (PD-L)-1(1–3). The aim of our study was to evaluate efficacy and clinical outcome ... Read more >>

()
[, :]

Cited: 0 times

View full text PDF listing >>



Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.

Gennaro Daniele, Francesco Raspagliesi, Giovanni Scambia, Carmela Pisano, Nicoletta Colombo, Simona Frezzini, Germana Tognon, Grazia Artioli, Angiolo Gadducci, Rossella Lauria, Annamaria Ferrero, Saverio Cinieri, Andrea De Censi, Enrico Breda, Paolo Scollo, Ugo De Giorgi, Andrea Alberto Lissoni, Dionyssios Katsaros, Domenica Lorusso, Vanda Salutari, Sabrina Chiara Cecere, Eleonora Zaccarelli, Margherita Nardin, Giorgio Bogani, Mariagrazia Distefano, Stefano Greggi, Maria Carmela Piccirillo, Roldano Fossati, Gaia Giannone, Laura Arenare, Ciro Gallo, Francesco Perrone, Sandro Pignata,

<h4>Objective</h4>To explore the clinical and biological prognostic factors for advanced ovarian cancer patients receiving first-line treatment with carboplatin, paclitaxel, and bevacizumab.<h4>Methods</h4>A multicenter, phase IV, single arm trial was performed. Patients with advanced (FIGO (International Federation of Gynecology and Obstetrics) stage IIIB-IV) or recurrent, previously untreated, ovarian cancer received carboplatin (AUC ... Read more >>

Int J Gynecol Cancer (International journal of gynecological cancer : official journal of the International Gynecological Cancer Society)
[2021, 31(6):875-882]

Cited: 1 time

View full text PDF listing >>



An Italian National Survey on Ovarian Cancer Treatment at first diagnosis. There's None so Deaf as those who will not Hear.

Vincenzo Dario Mandato, Federica Torricelli, Stefano Uccella, Debora Pirillo, Gino Ciarlini, Gabriele Ruffo, Gianluca Annunziata, Gloria Manzotti, Sandro Pignata, Lorenzo Aguzzoli,

<b>Objective:</b> Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy, crucial prognostic factors are no gross residual disease and centralization of cases. To evaluate the centralization of EOC patients, we report the results of a survey that shows the daily management of EOC patients in Italy. <b>Methods:</b> A 49-items ... Read more >>

J Cancer (Journal of Cancer)
[2021, 12(15):4443-4454]

Cited: 0 times

View full text PDF listing >>



Surveillance alone in stage I malignant ovarian germ cell tumors: a MITO (Multicenter Italian Trials in Ovarian cancer) prospective observational study.

Giorgia Mangili, Giorgio Giorda, Gabriella Ferrandina, Gennaro Cormio, Chiara Cassani, Antonella Savarese, Saverio Danese, Marco Carnelli, Francesca Maria Vasta, Anna Myriam Perrone, Giovanna Scarfone, Sandro Pignata, Francesco Legge, Francesco Raspagliesi, Gianluca Taccagni, Massimo Candiani, Giorgio Bogani, Floriana Mascilini, Alice Bergamini,

<h4>Objective</h4>The aim of this study was to analyze the oncological outcome of stage I malignant ovarian germ cell tumors patients included in the MITO-9 study to identify those who might be recommended routine surveillance alone after complete surgical staging.<h4>Methods</h4>MITO-9 was a prospective observational study analyzing data collected between January 2013 ... Read more >>

Int J Gynecol Cancer (International journal of gynecological cancer : official journal of the International Gynecological Cancer Society)
[2021, 31(9):1242-1247]

Cited: 0 times

View full text PDF listing >>



Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).

Kathleen N Moore, Michael Bookman, Jalid Sehouli, Austin Miller, Charles Anderson, Giovanni Scambia, Tashanna Myers, Cagatay Taskiran, Katina Robison, Johanna Mäenpää, Lyndsay Willmott, Nicoletta Colombo, Jessica Thomes-Pepin, Michalis Liontos, Michael A Gold, Yolanda Garcia, Sudarshan K Sharma, Christopher J Darus, Carol Aghajanian, Aikou Okamoto, Xiaohua Wu, Rustem Safin, Fan Wu, Luciana Molinero, Vidya Maiya, Victor K Khor, Yvonne G Lin, Sandro Pignata,

<h4>Purpose</h4>To evaluate the addition of the humanized monoclonal antiprogrammed death ligand-1 (PD-L1) antibody, atezolizumab, to platinum-based chemotherapy and bevacizumab in newly diagnosed stage III or IV ovarian cancer (OC).<h4>Methods</h4>This multicenter placebo-controlled double-blind randomized phase III trial (ClinicalTrials.gov identifier: NCT03038100) enrolled patients with newly diagnosed untreated International Federation of Gynecology and ... Read more >>

J Clin Oncol (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2021, 39(17):1842-1855]

Cited: 4 times

View full text PDF listing >>



Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21).

Grazia Artioli, Gaia Giannone, Giorgio Valabrega, Furio Maggiorotto, Sofia Genta, Sandro Pignata, Domenica Lorusso, Gennaro Cormio, Simona Scalone, Maria Ornella Nicoletto, Filippo Greco, Emanuela Rossi, Ilaria Spagnoletti, Ugo De Giorgi, Michele Orditura, Anna Maria Mosconi, Anila Kardhashi, Stefano Bogliolo, Lucia Borgato,

<h4>Objective</h4>Around 15% of epithelial ovarian cancer (EOC) patients (pts) harbor a germline BRCA1 or 2 mutation, showing different features than BRCA wild-type pts. The clinical and pathological features of an Italian BRCA mutated EOC cohort were described.<h4>Methods</h4>We retrospectively analyzed clinical, pathological and mutational data from a cohort of Italian BRCA ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2021, 161(3):755-761]

Cited: 0 times

View full text PDF listing >>



Uterine serous carcinoma.

Giorgio Bogani, Isabelle Ray-Coquard, Nicole Concin, Natalie Y L Ngoi, Philippe Morice, Takayuki Enomoto, Kazuhiro Takehara, Hannelore Denys, Remi A Nout, Domenica Lorusso, Michelle M Vaughan, Marta Bini, Masashi Takano, Diane Provencher, Alice Indini, Satoru Sagae, Pauline Wimberger, Robert Póka, Yakir Segev, Se Ik Kim, Francisco J Candido Dos Reis, Salvatore Lopez, Andrea Mariani, Mario M Leitao, Francesco Raspagliesi, Pieluigi Benedetti Panici, Violante Di Donato, Ludovico Muzii, Nicoletta Colombo, Giovanni Scambia, Sandro Pignata, Bradley J Monk,

Serous endometrial cancer represents a relative rare entity accounting for about 10% of all diagnosed endometrial cancer, but it is responsible for 40% of endometrial cancer-related deaths. Patients with serous endometrial cancer are often diagnosed at earlier disease stage, but remain at higher risk of recurrence and poorer prognosis when ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2021, 162(1):226-234]

Cited: 0 times

View full text PDF listing >>



Prognostic Evidence of the miRNA-Based Ovarian Cancer Signature MiROvaR in Independent Datasets.

Loris De Cecco, Marina Bagnoli, Paolo Chiodini, Sandro Pignata, Delia Mezzanzanica,

Epithelial ovarian cancer (EOC) remains the second most common cause of gynecological cancer deaths. To improve patients' outcomes, we still need reliable biomarkers of early relapse, of which external independent validation is a crucial process. Our previously established prognostic signature, MiROvaR, including 35 microRNAs (miRNA) able to stratify EOC patients ... Read more >>

Cancers (Basel) (Cancers)
[2021, 13(7):]

Cited: 0 times

View full text PDF listing >>



Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.

Robert L Coleman, Domenica Lorusso, Christine Gennigens, Antonio González-Martín, Leslie Randall, David Cibula, Bente Lund, Linn Woelber, Sandro Pignata, Frederic Forget, Andrés Redondo, Signe Diness Vindeløv, Menghui Chen, Jeffrey R Harris, Margaret Smith, Leonardo Viana Nicacio, Melinda S L Teng, Annouschka Laenen, Reshma Rangwala, Luis Manso, Mansoor Mirza, Bradley J Monk, Ignace Vergote, ,

<h4>Background</h4>Few effective second-line treatments exist for women with recurrent or metastatic cervical cancer. Accordingly, we aimed to evaluate the efficacy and safety of tisotumab vedotin, a tissue factor-directed antibody-drug conjugate, in this patient population.<h4>Methods</h4>This multicentre, open-label, single-arm, phase 2 study was done across 35 academic centres, hospitals, and community practices ... Read more >>

Lancet Oncol (The Lancet. Oncology)
[2021, 22(5):609-619]

Cited: 0 times

View full text PDF listing >>



Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.

Andrés Poveda, Anne Floquet, Jonathan A Ledermann, Rebecca Asher, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Sandro Pignata, Michael Friedlander, Alessandra Baldoni, Tjoung-Won Park-Simon, Kenji Tamura, Gabe S Sonke, Alla Lisyanskaya, Jae-Hoon Kim, Elias Abdo Filho, Tsveta Milenkova, Elizabeth S Lowe, Phil Rowe, Ignace Vergote, Eric Pujade-Lauraine, ,

<h4>Background</h4>Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously been shown to extend progression-free survival versus placebo when given to patients with relapsed high-grade serous or endometrioid ovarian cancer who were platinum sensitive and who had a BRCA1 or BRCA2 (BRCA1/2) mutation, as part of the SOLO2/ENGOT-Ov21 trial. The aim ... Read more >>

Lancet Oncol (The Lancet. Oncology)
[2021, 22(5):620-631]

Cited: 8 times

View full text PDF listing >>



Management of Metastatic Disease in Campania (MAMETIC): Epidemiologic Data and Palliative Radiotherapy in an Italian Region. Study Protocol

Rossella DI FRANCO, Marco Cascella, Mario Fusco, Valentina Borzillo, Piera Ferraioli, Esmeralda Scipilliti, Emma D'Ippolito, Angela Petito, Arturo Cuomo, Sandro Pignata, Marilena Di Napoli, Sabrina Rossetti, Egidio Celentano, Anna Crispo, Maria Grimaldi, Paolo Muto,

<h4>Background: </h4> . In the Italian Campania Region, 30.517 new cases of solid cancer have been diagnosed, in 2019. Of those, patients with metastatic disease are up to 20%. This class of patients is extremely diversified and copious, and the offer of radiotherapy may vary in different geographical areas within ... Read more >>

()
[, :]

Cited: 0 times

View full text PDF listing >>



Advertisement


Disclaimer

1.1319 s